Alzheimer's Disease
Editorial, BMJ 281:1374-13751980., , 1980
Bromocriptine in Parkinson Disease:Further Studies
Neurol 29:363-369, Lieberman,A.N.,et al, 1979
L-Dopa Therapy in Parkinson's Disease:Plasma L-Dopa Concentr. Therapeutic Response, & Side Effects
Mayo Clin Proc 46:231-239, Muenter,M.D.,et al, 1979
Comparative Effectiveness of Two Extracerebral DOPA Decarboxylase Inhibitors in Parkinson Disease
Neurol 28:964-968, Lieberman,A.,et al, 1978
Dopamine-Phenytoin Interaction, A Cause of Hypotension in the Critically Ill
Arch Surg 113:245-249, Bivins,B.A.,et al, 1978
Newer Concepts in Management of Migraine Headaches
J Med Soc N J 74:11, Haidri,N.H.,et al, 1977
Drug Therapy of Tardive Dyskinesia
NEJM 296:257, Kobayashi,R.M., 1977
Purine Phosphoribosyltransferase in Gilles de la Tourette Syndrome
NEJM 296:210, VanWoert,M.H.,et al, 1977
Successful Use of Bromocriptine in the treatment of a Patient with Chronic Portasystemic Encephalopathy
NEJM 296:793, Morgan,M.Y.,et al, 1977
Juvenile Parkinsonism Treated with Levodopa
Arch Neurol 34:244, Sachdev,K.K.,et al, 1977
Long-term Therapy of Myoclonus & Other Neurologic Disorders with L-5-Hydroxytryptophan & Carbidopa
NEJM 296:70, VanWoert,M.H.,et al, 1977
Postural Hypotension:Adrenergic Responsivity, & Levodopa Therapy
Neurol 27:921, Corder,C.N.,et al, 1977
Narcolepsy:REM Sleep Suppression by L-Dopa, (Letter)
NEMJ 294:849, Gilbert,J.C.,et al, 1976
Studies with Bromocriptine Part 2. Double-blind Comparison with Levodopa in Idiopathic Parkinsonism
Neurol 26:511, Kartzinel,R.,et al, 1976
Treatment of Parkinson's Disease with Bromocriptine
NEJM 295:1400, Lieberman,A.,et al, 1976
Developments in the Treatment of Parkinsonism
NEJM 295:1433, Calne,D.B., 1976
Progressive Supranuclear Palsy-Case Study
NEJM 293:346, Richardson,E.P., 1975
Catecholamines & Neurologic Diseases
NEJM 293:274, Moskowitz,M.A.,et al, 1975
Important Advances in Clinical Medicine
West J Med 123:128, Mosier,J.M.,et al, 1975
Huntington's Chorea-Deficiency of Y-Aminobutynic Acid in Brain
NEJM 288:337, 1973, 289:104, 1973, 292:10295., Perry,T.,et al, 1975
Facial Hyperkinesis
BMJ 626, Jun1974., , 1974
Presymptomatic Detection of Huntington's Chorea
BMJ 540, 1972 Sept., , 1972
Treatment of Parkinsonism
NEJM 287:1047, Young,R.R., 1972
Treatment for Parkinsonism
Other than Levodopa, BMJ 741, 1972 March., , 1972
Use of L-Dopa in the Detection of Presymptomatic Huntington's Chorea
NEJM 286:1332, Klawans,H.,et al, 1972
Modern Treatment of Parkinson's Disease
Excerpta Medica, 2:1972 Sept., , 1972
Implications of Amphetamine-Induced Stereotyped Behavior as a Model for Tardive Dyskinesias
Arch Gen Psychiat 27:502-507, Rubovits,R.,et al, 1972
Levodopa Therapy:Why Wait? Patient Care June 15
1971., , 1971
Combined Treatment of Parkinsonian Tremor with Propranolol & Levodopa
J Neurol Sci 14:491, , 1971
Cholinergic & Dopaminergic Mechanisms in Huntington's Chorea
Life Sciences 10:405 1971., Aquilonius,S.,et al, 1971
Modern Treatment of Parkinson's Disease
Excerpta Medica l:Nov-Dec, , 1971
Modern Treatment of Parkinson's Disease
Excerpta Medica 2:1971 Oct., , 1971
How does L-Dopa Work in Parkinsonism
Lancet 784, 1971 Apr., Sandler,M., 1971
L-Dopa in the Treatment of Parkinson's Disease
Postgrad Med 47:153, Martin,W., 1970
Dopamine & Disease
C M A Journ 103:824, Barbeau,A., 1970
Neuropsychopharmcology & the Affective Disorders
NEJM 281:197, 1969 (three parts) ., Schildkraut,J.J., 1969
An 81-Year-Old Man with Imbalance and Memory Impairment
, Golbe,L.I.,et al,
Stroke Mechanism and Severity after Left Atrial Appendage Occlusion, Insights from the LAAOS III Randomized Clinical Trial
JAMA Neurol 83:76-82, Katsanos,A.H.,et al, 2026
Disease-Modifying, Neuroprotective Effect of N-Acetyl-L-Leucine in Adult and Pediatric Patients with Neimann-Pick Disease Type C
Neurol 105:e213589, Patterson,M.C., et al, 2025
Left Atrial Appendage Occlusion and Its Role in Stroke Prevention
Stroke 56:1928-1937, Seiffge,D.J.,et al, 2025
Collaboration on the Optimal Timing of Anticoagulation after Ischaemic Stroke and Atrial Fibrillation:A Systematic Review and Prospective Individual Participant Data Meta-Analysis of Randomised Controlled Trials (CATALYST)
Lancet 406:43-51, Dehbi,K-M.,et al, 2025
Residual Risk of Recurrent Stroke Despite Anticoagulation in Patients with Atrial Fibrillation,A Systematic Review and Meta-Analysis
JAMA Neurol 82:696-705, McCabe,J.J.,et al, 2025
Cerebral Air Embolism Caused by Atrial-Esophageal Fistula Following Left Atrial Ablation
Stroke 56:e195-e199, Masheyekhi,M.,et al, 2025
Clinicopathologic Conference, Lyme Carditis
NEJM 393:799-807, Case 24-2025, 2025
Clinicopathologic Conference, Chagas Disease
NEJM 393:1216-1225, Case 27-2025, 2025
Left Atrial Appendage Closure After Ablation for Atrial Fibrillation
NEJM 392:1277-1287, Wazni,O.M.,et al, 2025
Anticoagulation or Antiplatelet Therapy for Device-Detected Atrial Fibrillation
NEJM 392:1749-1751, Gorey,S., 2025
Recurrent Ischemic Stroke in Patients with Atrial Fibrillation Whle Receiving Oral Anticoagulants
JAMA Neurol 81:805-813, Hindsholm,M.F.,et al, 2024
Anticoagulation vs Antiplatelets Across Subgroups of Embolic Stroke of Undetermined Source
Neurol 103:e209949, Grannam,M.,et al, 2024
Optimal Timing of Anticoagulation after Acute Ischaemic Stroke with Atrial Fibrillation (OPTIMAS): A Multicentre, Blinded-Endpoint, Phase 4, Randomised Controlled Trial
Lancet 404:1731-1741, Werring,D.J.,et al, 2024